摘要
目的探讨静脉注射蔗糖铁(森铁能)治疗血液透析(HD)患者肾性贫血的有效性和安全性。方法60例患者随机分为蔗糖铁组和乳酸亚铁口服液组,每组30例。蔗糖铁组:每周1次透析时从透析管路静脉端将蔗糖铁100mg+10ml生理盐水静脉推注;口服铁组:乳酸亚铁口服液100mg,3次/d,两组患者观察10周;均同时使用基因重组人红细胞生成素(EPO)6000～8000U/周,分两次皮下注射。比较两组患者贫血治疗的疗效与安全性。结果治疗后患者的贫血均有改善,但蔗糖铁组在血红蛋白(Hb),血细胞比容(HCT),血清铁蛋白(SP),转铁蛋白饱和度(TSAT)与治疗前及口服组比较,差异有统计学意义。治疗前后,两组患者血清BUN、SCr、ALT和AST等无明显变化。静脉组患者无明显不良反应,口服组13.3%(4/30)出现消化道反应。结论蔗糖铁治疗肾性贫血是安全有效的。
Objective To evaluate efficacy and safety of intravenous iron sucrose in anemic hemodiaiysis（HD） patients. Methods 60 patients were divided into experimental group（ n = 30} treated with intravenous iron sucrose and control group（ n = 30） treated with feyrous lactate oral solution randomly. 100mg of iron sucrose with 10ml of physiological saline was given through the dialysis tube at the first time of dialysis of each week in experimental group;and feyrous lactate oral solution was given lOOmg rid in the control group. Observation period was 10 weeks. And genetic recombination human erythropoiesis（ EPO） was given 6000 - 8000U/week in two subcutaneous injections. Efficacy and safety of each drug was evaluated. Results anemia was ameliorated in both groups, while Hb, Het, serum ferritin（SF） and transferin saturation（TSAT） was higher in the experimental group than the control with ignificant difference. Senum BUN, creatine, ALT and AST did not change ＇alter treatment. No obvious adverse drug reactions happened in the experimental group, while 13.4% （4 in 30） patients in the control group had gastrointestinal adverse drug reactions. Conclusion Intravenous iron sucrose is effec- tive and safe in treating anemia in CKD patients.
出处
《四川医学》
CAS
2008年第8期982-983,共2页
Sichuan Medical Journal
